NIOSH REL: TWA 100 ppm (410 mg/m3), IDLH 1,000 ppm; OSHA PEL:
TWA 100 ppm; ACGIH TLV: TWA 100 ppm with intended TWA and STEL values of 50 and
100 ppm, respectively.
LogP:
1.38 at 20℃
物理描述:
Methyl methacrylate monomer appears as a clear colorless liquid. Slightly soluble in water and floats on water. Vapors heavier than air. Vapors irritate the eyes and respiratory system. Containers must be heavily insulated or shipped under refrigeration. An inhibitor such as hydroquinone, hydroquinone methyl ester and dimethyl t-butylphenol is added to keep the chemical from initiating polymerization. The chemical may polymerize exothermically if heated or contaminated with strong acid or base. If the polymerization takes place inside a container, the container may rupture violently. Used to make plastics.
The monomer tends to self-polymerize and this may become explosive ... Exposure of the purified (unstabilized) monomer to air at room temp for 2 months generated an ester-oxygen interpolymer, which exploded on evaporation of the surplus monomer at 60 °C (but not at 40 °C).
The metabolism of MMA was studied in male Wistar rats after oral gavage of MMA radiolabeled on the C2 position (5.7 mg/kg) or the methyl group attached to the C2 (120 mg/kg) in corn oil. A total of 65% of a single dose of methyl (1,3-(14)C)propylene-2-carboxylate or methyl (2-(14)C)-propylene-2-carboxylate was exhaled as (14)CO2 within 2 hr of administration, and 76 - 88% was exhaled with 10 days. Pulmonary excretion of unchanged MMA accounted for < 1% of the dose in the case of methyl (1,3-(14)C)propylene-2-carboxylate (5.7 mg/kg) and for 1.4% of the dose after 120 mg/kg of methyl (2-(14)C)propylene-2-carboxylate. Approximately 50% of the remaining dose was excreted in urine, the remainder being retained in body tissues after 10 days. The elimination pattern did not differ significantly with the dose, but MMA was metabolized more slowly at the higher dose. From the urine of rats treated with methyl (1,3-(14)C)propylene-2-carboxylate, the following (14)C-containing metabolites were identified: methacrylic acid (0.8% of the dose), methylmalonic acid (1.1%), succinic acid (0.2%), 2 minor metabolites co-eluting with beta-hydroxyisobutyric acid and formyl-2-propionic acid (methylmalonic semialdehyde). (14)C urea (2%) and H14CO3- were assumed to be derived from (14)CO2. The authors conclude that MMA is metabolized via physiological pathways and enters into the citric acid cycle via methyl-malonyl CoA and succinyl-CoA, which is a part of the valine pathway.
... The in vitro metabolism of MMA /was studied/ using liver slices of male Wistar rats. Some of the preparations were preincubated with inhibitors of certain steps of the citric acid cycle, arsenite (1 mM) or malonate (10 mM). Metabolism of MMA was compared to that of the natural intermediate of the citric acid cycle, fumarate, and found to be very similar. As malonate was not found to inhibit MMA metabolism, but arsenite inhibited it very effectively, the authors concluded that MMA is metabolized via pyruvate rather than succinyl-CoA.
Following the addition of 0, 2, 5 and 10 mM MMA to isolated rat hepatocyte preparations and incubation for 2 hr at 37 °C, a concentration and time dependent depletion of reduced glutathione (GSH) in the cells was observed. A minimum GSH content was reached after 30 min incubation. GSH levels then returned to normal, the time required being a function of the MMA concentration. After 2 hr the concentration-related GSH depletion was still observable. The viability of the hepatocytes, monitored by the integrity of the plasma membrane, was not impaired by MMA treatment. MMA had no effect on the content of cytochrome P-450 hemoprotein of the cells.
Methyl methacrylate (1 mM or 5 mM) did not react with GSH (2 mM) in phosphate buffer (pH 6.5) when incubated with 25% rat liver supernatant for 1 or 3 hr. The enzyme glutathione-S-epoxide transferase was not active in the presence of MMA as determined by GSH loss. Although a separate enzyme in rat liver supernatant, catalyzing the reaction of alpha, beta-unsaturated compounds with GSH could be identified, this enzyme did not catalyze the reaction of MMA with GSH.
IDENTIFICATION: Methyl methacrylate is a volatile synthetic chemical that is used principally in the production of cast acrylic sheet, acrylic emulsions, and molding and extrusion resins. HUMAN EXPOSURE: Data on absorption following dermal exposure are limited. In humans, methyl methacrylate is rapidly metabolized to methacrylic acid. This compound is a mild skin irritant in humans and has the potential to induce skin sensitization in susceptible individuals. Although occupational asthma associated with methyl methacrylate has also been reported, there is no conclusive evidence that this compound is a respiratory sensitizer. Epidemiological studies do not provide strong or consistent evidence of a carcinogenic effect of methyl methacrylate on any target organ in humans, nor can it be inferred with any degree of confidence that the possibility of an increased risk has been disapproved. ANIMAL/PLANT STUDIES: Methyl methacrylate is rapidly absorbed and distributed following inhalation or oral administration to experimental animals. Data on absorption following dermal exposure are limited. In experimental animals, methyl methacrylate is rapidly metabolized to methacrylic acid. Following inhalation, 16-20% of the chemical is deposited in the upper respiratory tract of rats, where it is primarily metabolized by local tissue esterases. The acute toxicity of this compound is low. Irritation of the skin, eye and nasal cavity has been observed in rodents and rabbits exposed to relatively high concentrations of methyl methacrylate. The chemical is a mild skin sensitizer in animals. The effect observed most frequently at the lowest concentration after repeated inhalation exposure to this compound is irritation of the nasal cavity. Effects on the kidney and liver at higher concentrations have been reported. The lowest reported effect level for irritation was 410 mg/cu m in rats exposed to this material for 2 yr (based upon inflammatory degeneration of the nasal epithelium); the no observed effect level (NOEL) in this investigation was approximately 100 mg/cu m. In a study in rats, there were no developmental effects, although there were decreases in maternal body weight following inhalation of concentrations up to 8,315 mg/cu m. There was no reduction in fertility in a dominant lethal assay in mice exposed to this compound at concentrations up to 36,900 mg/cu m and no adverse effects on reproductive organs in repeated dose studies conducted to date. Available data on the neurotoxicity of methyl methacrylate are limited; impairment of locomotor activity and learning and behavioral effects on the brain were observed in rats exposed orally to 500 mg/kg bw/day for 21 days. Methyl methacrylate was not carcinogenic in an extensive well documented 2 yr bioassay in rats and mice exposed by inhalation and in additional chronic inhalation studies in rats and hamsters. This substance is not mutagenic in in vitro bacterial systems, this compound is mutagenic and clastogenic in mammalian cells in vitro. In in vivo studies (primarily by the inhalation route) in which there has been clear evidence of toxicity within the target tissue, there has been limited evidence of the genotoxicity of methyl methacrylate. The toxicity of methyl methacrylate to aquatic organisms is low. No chronic studies on aquatic organisms were identified. Acute tests have been conducted on fish, Daphnia magna and algae. The most sensitive effect was the onset of inhibition of cell multiplication by the green alga Scenedesmus quadricauda at 37 mg/l following an 8 day exposure period. The lowest EC50 for immobilization in Daphnia was 720 mg/L. The 96 hr LC50 for juvenile bluegill sunfish (Lepomis macrochirus) under flow through conditions was 191 mg/L, whereas LC50 values for durations 1-24 hr ranged from 420-356 mg/L, respectively. The 96 hr LC50 for rainbow trout (Oncorhynchus mykiss) under flow through conditions was > 79 mg/L, the highest concentration tested. Sublethal/behavioral responses were noted among the fish at 40 mg/L.
Evaluation: There is inadequate evidence in humans for the carcinogenicity of methyl methacrylate. There is evidence suggesting lack of carcinogenicity of methyl methacrylate in experimental animals. Overall evaluation: Methyl methacrylate is not classifiable as to its carcinogenicity to humans (Group3).
WEIGHT OF EVIDENCE CHARACTERIZATION: Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, MMA would be classified as evidence of non-carcinogenicity for humans or a Group E chemical. Under the Proposed Guidelines for Carcinogenic Risk Assessment, MMA is considered not likely to be carcinogenic to humans by any route of exposure because it has been evaluated in four well-conducted chronic inhalation studies in three appropriate animal species without demonstrating carcinogenic effects. Basis - The results of the 2-year inhalation studies conducted for NTP showed no evidence of carcinogenicity of MMA for male F344/N rats exposed at 500 or 1,000 ppm, for female F344/N rats exposed at 250 or 500 ppm, or for female B6C3F1 mice exposed at 500 or 1,000 ppm. In addition, no increase was seen in the number or type of tumors in either rats or hamsters from the chronic inhalation study performed by Hazelton Laboratories /in 1979/. No carcinogenic activity was reported in a chronic oral study. Fewer animals were used and the experimental protocol and results of this oral study were not as well documented as for the inhalation study. However, acute oral exposure studies and structure-activity relationship comparisons with other acrylates suggest that the introduction of a methyl group to the acrylate moiety (e.g., EC to MMA) negates carcinogenic activity. Epidemiology studies show no clear excess of cancer. Though a report suggesting increased colon cancer among ethyl acrylate/MMA-exposed workers exists, a high background for this effect has been documented for the location and time of this study, the effects were not reproduced in other similar and more recent studies, a clear relationship between exposure and effect was not demonstrated, and the extent that ethyl acrylate concurrent exposure confounded results could not be determined. Given these structure-activity relationship considerations, the low potential for cancer from MMA exposure indicated in genotoxicity, laboratory animal and epidemiology studies suggests that MMA does not represent a carcinogenic hazard to humans. HUMAN CARCINOGENICITY DATA: Inadequate. ANIMAL CARCINOGENICITY DATA: No evidence.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌性证据
A4;不可分类为人类致癌物。
A4; Not classifiable as a human carcinogen.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
国际癌症研究机构致癌物:甲基丙烯酸甲酯
IARC Carcinogenic Agent:Methyl methacrylate
来源:International Agency for Research on Cancer (IARC)
The tissue distribution of radioactivity after iv administration of 1,3-(14)C-methyl methacrylate (10 mg/kg, 50 uCi/kg in polyethyleneglycol 2000/ethanol 1:1) to three male Alderley Park rats was studied by whole body autoradiography. The rats were killed at 2, 5, and 15 min after dosing. Irrespective of the time of sacrifice, the greatest concentrations of radioactivity were determined in blood, heart, lungs, liver, kidneys, and salivary glands. Other tissues containing smaller amounts of radioactivity included the testes, where some of the radioactivity was located in the seminal vesicles. In this study it was not possible to determine whether the radioactivity in any of the tissues was due to the presence of MMA or its metabolites.
After dermal exposure of 11 dental technicians to MMA for 30 - 240 min (dose levels not reported), 19 - 200 nmol methacrylate were excreted in the urine within 24 hr of exposure. Since there was no measurement of the exposure concentration in this study, it was impossible to make a correlation between exposure and urinary levels. Excreted methacrylate concentrations showed a wide interindividual variability and were not consistently related to exposure time. The authors state that inhalation exposure would not give the observed methacrylate urine levels due to the usually low workplace concentrations in dental laboratories. Air levels were not determined in the study however.
Blood samples of 69 patients with a hip arthroplasty, receiving about 48 g of a half-cured methacrylate bone cement, were taken 10, 30, 60, and 120 sec, 3 ,4, 5, 6, 8, and 10 min after the implantation. Concentrations of the monomer varied widely between the patients. Maximum blood levels were obtained between 30 and 60 sec after implantation, with mean concentrations of 0.8 - 1.2 ug/mL. The highest concentration obtained was 16 ug/mL. In samples taken after 3 and 6 min, no MMA could be detected.
Samples of venous and arterial blood of 11 patients receiving joint prostheses using MMA based bone cement were taken 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 7 min after introduction of the bone cement either into the cotyloid cavity or into the femur. The samples were analyzed for MMA content by GC. After introducing the bone cement into the cotyloid cavity, venous blood levels were higher than when the bone cement was applied to the femur. Arterial blood levels were significantly lower than venous blood levels. The highest MMA concentrations in venous blood (> 1 ug/mL) were reached 1.4 min after exposure. The elimination of MMA followed biexponential kinetics with an initial half-life of 0.3 min and a terminal half-life of 3 min.
Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.
[EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
申请人:ASTRAZENECA AB
公开号:WO2016055858A1
公开(公告)日:2016-04-14
The present application relates to compounds of formula (I), (la), or (lb) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Αβ-related pathologies such as Down's syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.
Total Synthesis of Hybocarpone and Analogues Thereof. A Facile Dimerization of Naphthazarins to Pentacyclic Systems
作者:K. C. Nicolaou、David L. F. Gray
DOI:10.1021/ja030497n
日期:2004.1.1
The total synthesis of the lichen-derived antitumor agent hybocarpone (1) and related compounds is described. The successful route to hybocarpone features a novel radical-based dimerization/hydration cascade which generates the bridging hindered carbon-carbon bond of the molecule in a stereocontrolled manner, setting the relative configurations of the four contiguous stereocenters in a single step
Ultra‐High‐Molecular‐Weight Polymers Produced by the Immortal Phosphine‐Based Catalyst System
作者:Yun Bai、Jianghua He、Yuetao Zhang
DOI:10.1002/anie.201811946
日期:2018.12.21
promote the frustrated Lewis pair (FLP)‐catalyzed living polymerization of methyl methacrylate (MMA), achieving ultrahigh molecular weight (UHMW) poly(methyl methacrylate) (PMMA) with Mn up to 1927 kg mol−1 and narrow molecular weight distribution (MWD) at room temperature (RT). This FLP catalyst system exhibits exceptionally long lifetime polymerization performance even in the absence of free MMA, which
强大的有机磷超碱N-(二苯基膦基)-1,3-二异丙基-4,5-二甲基-1,3-二氢-2H-咪唑-2-亚胺(IAP3)与位阻但适度为酸性的路易斯酸结合使用(LA),(4-Me- 2,6 - t Bu 2 -C 6 H 2 O)Al i Bu 2((BHT)Al i Bu 2),以协同促进沮丧的Lewis对(FLP)催化的生活聚合甲基丙烯酸甲酯(MMA),实现M n高达1927 kg mol -1的超高分子量(UHMW)聚甲基丙烯酸甲酯(PMMA)和在室温(RT)下较窄的分子量分布(MWD)。该FLP催化剂体系即使在不存在游离MMA的情况下,也表现出异常长的聚合寿命,这可以在将所得体系在室温下放置24小时后重新引发所需的活性聚合。
作者:Alistair J. M. Farley、Christopher Sandford、Darren J. Dixon
DOI:10.1021/jacs.5b10226
日期:2015.12.30
The highly enantioselective sulfa-Michael addition of alkyl thiols to unactivated α-substituted acrylate esters catalyzed by a bifunctional iminophosphorane organocatalyst under mild conditions is described. The strong Brønsted basicity of the iminophosphorane moiety of the catalyst provides the necessary activation of the alkyl thiol pro-nucleophile, while the two tert-leucine residues flanking a